AIM Rule 26

The following information is disclosed in accordance with AIM Rule 26

Summit Therapeutics is a biotechnology company focussed on the development of new mechanism antibiotics.  Click on the following link for a description of our business

Registered name: Summit Therapeutics plc
Country of incorporation: England & Wales
Main country of operation: United Kingdom
Registered address: 136a Eastern Avenue Milton Park Abingdon Oxfordshire OX14 4SB United Kingdom
Company Secretary: Melissa Strange, FCCA
Registered number: 05197494
VAT number: 876331407

 

The Company’s current articles of association can be viewed here:

Articles of Association

Summit’s shares are traded on the AIM market of the London Stock Exchange and Nasdaq Global Market.  Click here  for more information about number of securities in issue and, insofar as the company is aware, the percentage of AIM securities not in public hands, together with the identity and percentage of significant shareholders.

Click here for access to the Company’s Annual and Interim Reports.

Click here to view all regulatory news notifications made by the Company.

The Company’s Admission Document to AIM, a market of the London Stock Exchange is available:

IPO Admission Document

Please note this document was issued more than twelve years ago and is accordingly substantially
out of date. For more accurate and up-to-date information, please refer to other sections of this website, the latest Annual Report, our filings with the US Securities & Exchange Commission, recent regulatory announcements and other such information
sources on the web.

We are committed to maintaining a high standard of corporate governance. Click here for further details about our approach.

Summit Therapeutics plc is subject to the UK City Code on Takeovers and Mergers.

Click here for details of the Company’s advisers.
This section of the website, and the information that can be accessed from this page, was last updated to comply with AIM Rule 26 on: 30 April 2018